Filtered By:
Drug: Methotrexate

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 289 results found since Jan 2013.

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial
Conclusions In this group of patients with early inflammatory arthritis, almost a third had no tender, swollen joints after 1 year. MTX+ETN was not superior to MTX monotherapy in achieving this outcome. Clinical responses, however, including DAS28-CRP<2.6, were achieved earlier with MTX+ETN combination therapy. Trial registration number The EMPIRE trial is registered on the following trial registries: Eudract-2005-005467-29; ISRCTN 55428162 (http://www.controlled-trials.com/ISRCTN55428162/EMPIRE). The full trial protocol can be obtained from the corresponding author.
Source: Annals of the Rheumatic Diseases - April 30, 2014 Category: Rheumatology Authors: Nam, J. L., Villeneuve, E., Hensor, E. M. A., Wakefield, R. J., Conaghan, P. G., Green, M. J., Gough, A., Quinn, M., Reece, R., Cox, S. R., Buch, M. H., van der Heijde, D. M., Emery, P. Tags: Immunology (including allergy), Degenerative joint disease, Musculoskeletal syndromes, Epidemiology Clinical and epidemiological research Source Type: research

A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks
Conclusions At 6 months COBRA-light therapy is most likely non-inferior to COBRA therapy. Clinical Trial Registration Number 55552928.
Source: Annals of the Rheumatic Diseases - April 30, 2014 Category: Rheumatology Authors: den Uyl, D., ter Wee, M., Boers, M., Kerstens, P., Voskuyl, A., Nurmohamed, M., Raterman, H., van Schaardenburg, D., van Dillen, N., Dijkmans, B., Lems, W. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
Conclusions In early active RA, intra-articular betamethasone injections added to disease-modifying antirheumatic drug (DMARD) treatment led to minimal loss of hip and lumbar BMD, and the loss could be prevented by treatment with alendronate. Alendronate treatment did not affect radiographic progression.
Source: Annals of the Rheumatic Diseases - April 30, 2014 Category: Rheumatology Authors: Jensen, T. W., Hansen, M. S., Horslev-Petersen, K., Hyldstrup, L., Abrahamsen, B., Langdahl, B., Zerahn, B., Podenphant, J., Stengaard-Petersen, K., Junker, P., Ostergaard, M., Lottenburger, T., Ellingsen, T., Andersen, L. S., Hansen, I., Skjodt, H., Pede Tags: Immunology (including allergy), Radiology, Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Radiology (diagnost Source Type: research

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Conclusions Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add-on and switch strategies led to meaningful clinical and radiographic responses.
Source: Annals of the Rheumatic Diseases - April 4, 2014 Category: Rheumatology Authors: Dougados, M., Kissel, K., Conaghan, P. G., Mola, E. M., Schett, G., Gerli, R., Hansen, M. S., Amital, H., Xavier, R. M., Troum, O., Bernasconi, C., Huizinga, T. W. J. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy
Conclusions Rapid suppression of synovitis and osteitis with reduction in structural joint damage progression occurred with TCZ, as monotherapy or in combination with MTX, through week 52.
Source: Annals of the Rheumatic Diseases - April 4, 2014 Category: Rheumatology Authors: Conaghan, P. G., Peterfy, C., Olech, E., Kaine, J., Ridley, D., DiCarlo, J., Friedman, J., Devenport, J., Troum, O. Tags: Open access, Immunology (including allergy), Bone and joint infections, Radiology, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Radiology (diagnostics), Calcium and bone Source Type: research

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
Conclusions Adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment did not increase the proportion of patients who reached the DAS28CRP<3.2 treatment target, but improved DAS28CRP, remission rates, function and quality of life in DMARD-naïve ERA.
Source: Annals of the Rheumatic Diseases - February 27, 2014 Category: Rheumatology Authors: Horslev-Petersen, K., Hetland, M. L., Junker, P., Podenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Ammitzboll, C. G., Jorgensen, A., Krintel, S. B., Raun, J., Johansen, J. S., Tags: Editor's choice, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study
Conclusions Persistence of MenC-specific IgG antibodies in JIA patients is similar to healthy controls, but treatment with biologicals may induce accelerated antibody waning, resulting in unprotected patients who may need revaccination.
Source: Annals of the Rheumatic Diseases - February 27, 2014 Category: Rheumatology Authors: Stoof, S. P., Heijstek, M. W., Sijssens, K. M., van der Klis, F., Sanders, E. A. M., Teunis, P. F. M., Wulffraat, N. M., Berbers, G. A. M. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Conclusions Addition of low-dose glucocorticoids to csDMARD therapy produces benefits in early RA. Under tight control conditions, combination therapy with csDMARDs is no better than MTX monotherapy. Tofacitinib is a new DMARD with proven efficacy.
Source: Annals of the Rheumatic Diseases - February 4, 2014 Category: Rheumatology Authors: Gaujoux-Viala, C., Nam, J., Ramiro, S., Landewe, R., Buch, M. H., Smolen, J. S., Gossec, L. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Conclusions The findings from this SLR confirm the known safety pattern of sDMARDs and bDMARDs for the treatment of RA.
Source: Annals of the Rheumatic Diseases - February 4, 2014 Category: Rheumatology Authors: Ramiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., Landewe, R. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
Conclusions Adalimumab in combination with low-dose MTX was well tolerated and efficacious in suppressing radiographic progression and improving clinical outcomes in Japanese patients with early RA and high disease activity.
Source: Annals of the Rheumatic Diseases - February 4, 2014 Category: Rheumatology Authors: Takeuchi, T., Yamanaka, H., Ishiguro, N., Miyasaka, N., Mukai, M., Matsubara, T., Uchida, S., Akama, H., Kupper, H., Arora, V., Tanaka, Y. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study)
Conclusions After 5 years there is no lasting benefit of a 1 year initial course of MTX for patients with undifferentiated arthritis, compared with initial placebo. Progression to classifiable RA was not suppressed, drug-free remission not induced and the progression of radiological damage was similar in both groups. Reclassification at baseline with the 2010 criteria showed that 25% of patients with RA (2010) achieved spontaneous drug-free remission.
Source: Annals of the Rheumatic Diseases - December 30, 2013 Category: Rheumatology Authors: van Aken, J., Heimans, L., Gillet-van Dongen, H., Visser, K., Ronday, H. K., Speyer, I., Peeters, A. J., Huizinga, T. W. J., Allaart, C. F. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Methotrexate-induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis.
CONCLUSIONS: In MTX-P, cytological analysis of BAL may disclose up to six different patterns. In MTX-P affecting cancer patients, BAL tends to show the typical features of hypersensitivity pneumonitis, while, in rheumatoid arthritis patients, it is more heterogeneous, with a less intense lymphocytosis, a more pronounced neutrophilia, and a higher CD4/CD8 ratio. These differences could be related to a disparity in baseline pulmonary conditions between the two background diseases, i.e., to the presence of previously healthy lungs in cancer patients, and lungs already involved by the immune-mediated inflammatory processes, of...
Source: Inflammation and Allergy Drug Targets - December 29, 2013 Category: Allergy & Immunology Authors: D'Elia T Tags: Inflamm Allergy Drug Targets Source Type: research

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Conclusions Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E. M., Montecucco, C. M., McInnes, I., Radner, H., Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Osteoporosis, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
Conclusions In DMARD-naive early RA patients, initial therapy with MTX+high-dose intravenous steroid resulted in good disease control with little structural damage. MTX+IFX was not statistically superior to MTX+intravenous steroid when combined with a treat-to-target approach.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Nam, J. L., Villeneuve, E., Hensor, E. M. A., Conaghan, P. G., Keen, H. I., Buch, M. H., Gough, A. K., Green, M. J., Helliwell, P. S., Keenan, A. M., Morgan, A. W., Quinn, M., Reece, R., van der Heijde, D. M., Wakefield, R. J., Emery, P. Tags: Immunology (including allergy), Radiology, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Radiology (diagnostics), Epidemiology Clinical and epidemiological research Source Type: research

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Conclusions Through 2 years of blinded treatment in this first head-to-head study between biologic disease-modifying antirheumatic drugs in RA patients with an inadequate response to MTX, subcutaneous abatacept and adalimumab were similarly efficacious based on clinical, functional and radiographic outcomes. Overall, AE frequency was similar in both groups but there were less discontinuations due to AEs, SAEs, serious infections and fewer local ISRs with abatacept. ClinicalTrials.gov Identifier NCT00929864.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Schiff, M., Weinblatt, M. E., Valente, R., van der Heijde, D., Citera, G., Elegbe, A., Maldonado, M., Fleischmann, R. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research